Diamyd Medical AB (DMYD B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Diamyd Medical AB (DMYD B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH1150415D
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Diamyd Medical AB (Diamyd), formerly Diamyd Therapeutics AB is a drug company that concentrates on the development of therapies for autoimmune diabetes. The company is developing diabetes vaccine, Diamyd, an Antigen Based Therapy (ABT). It develops therapies based on its in-licensed substances GAD, GABA and Gliadin for the prevention and treatment of autoimmune diabetes and other inflammation-related conditions. Its GAD is the active ingredient in the diabetes vaccine Diamyd; GABA (gamma-aminobutyric acid) is synthesized from the amino acid glutamate in cells by the enzyme GAD; and Gliadin is a constituent of gluten protein found in wheat and some other cereals. The company invests in the stem cell and medical technology. Diamyd is headquartered in Stockholm, Sweden.

Diamyd Medical AB (DMYD B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Diamyd Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Diamyd Medical AB, Medical Devices Deals, 2011 to YTD 2017 10

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Diamyd Medical Enters into Agreement with TFS Trial Form Support 12

Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 12

Licensing Agreements 13

Diamyd Medical Enters into Licensing Agreement for Gliadin 13

Equity Offering 14

Diamyd Medical Raise USD10 Million in Rights Offering of Units 14

Diamyd Medical Raises USD2.6 Million in Rights Offering of shares 15

Diamyd Medical to Raise USD1.7 Million in Private Placement of Series B Shares 16

Acquisition 17

Diamyd Medical Acquires 16% Stake in NextCell Pharma 17

Diamyd Medical AB-Key Competitors 18

Key Employees 19

Locations And Subsidiaries 20

Head Office 20

Recent Developments 21

Financial Announcements 21

Apr 05, 2017: Diamyd Medical: Quarterly Report II 16/17 21

Jan 25, 2017: Diamyd Medical: Quarterly Report I 16/17 25

Jun 29, 2016: Diamyd Medical: Quarterly Report III 15/16 26

Apr 06, 2016: Diamyd Medical: Quarterly Report II 15/16 27

Jan 20, 2016: Diamyd Medical: Quarterly Report I 15/16 30

Corporate Communications 33

Jan 10, 2017: GABA-specialist to the Board of Diamyd Medical 33

Apr 11, 2016: Diamyd Medical appoints new CEO 34

Product News 35

Sep 09, 2016: Diamyd Medical expands activities to both type 1 and type 2 diabetes as well as rheumatoid arthritis with proprietary GABA drug 35

Apr 21, 2016: Interim results from DIAGNODE-1 indicate clear and desired re-balancing of the immune system after administration of Diamyd directly into lymph nodes 36

Jan 20, 2016: Diamyd Medical plans first interim report from the study DIAGNODE-1 where the diabetes vaccine Diamyd is administered directly into lymph nodes 39

Clinical Trials 40

Apr 01, 2016: Study where Diamyd is administered directly into lymph nodes approved for expansion and inclusion of children from 12 years of age 40

Mar 23, 2016: Diamyd in combination with etanercept and vitamin D shows safety in a first preliminary interim report 41

Feb 11, 2016: Diamyd administered directly into lymph nodes in young adults with type 1 diabetes-preliminary interim report from DIAGNODE-1 43

Other Significant Developments 45

Nov 29, 2016: Diamyd Medical has appointed FNCA Sweden AB as Certified Adviser 45

Aug 02, 2016: Diamyd Medical's associated company Cellaviva is appointed European distributor for StemBioSys 46

Apr 20, 2016: Diamyd Medical increases strategic investment in the stem cell company Cellaviva 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48

List of Figures

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Diamyd Medical AB, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Diamyd Medical AB, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Diamyd Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Diamyd Medical AB, Deals By Therapy Area, 2011 to YTD 2017 9

Diamyd Medical AB, Medical Devices Deals, 2011 to YTD 2017 10

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Diamyd Medical Enters into Agreement with TFS Trial Form Support 12

Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 12

Diamyd Medical Enters into Licensing Agreement for Gliadin 13

Diamyd Medical Raise USD10 Million in Rights Offering of Units 14

Diamyd Medical Raises USD2.6 Million in Rights Offering of shares 15

Diamyd Medical to Raise USD1.7 Million in Private Placement of Series B Shares 16

Diamyd Medical Acquires 16% Stake in NextCell Pharma 17

Diamyd Medical AB, Key Competitors 18

Diamyd Medical AB, Key Employees 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Diamyd Medical AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16005
Site License
USD 500 INR 32010
Corporate User License
USD 750 INR 48015

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com